ReportWire

Tag: medical privacy

  • There’s One Big Problem With the New Federal Data Privacy Bill

    There’s One Big Problem With the New Federal Data Privacy Bill

    [ad_1]

    Americans have wanted a federal privacy law for years but intensive lobbying by the tech industry and general incompetence by our federal legislators has repeatedly thwarted that desire. Well, in 2024, it’s possible that we may finally get a strong federal privacy law.

    I’ll say it again: It’s possible. It’s also technically possible that frogs could rain from the sky over lower Manhattan, coating New Yorkers in a spring shower of amphibious guts, but is that actually likely to happen?

    The American Privacy Rights Act of 2024, recently introduced by Cathy McMorris Rodgers (R-WA) and Maria Cantwell (D-WA), would create basic digital privacy protections for Americans. The law, if enacted, would create a variety of protections and rights for consumers, including the ability to access, control, and delete information collected by companies.

    While that may sound like a good thing, there’s one aspect of the legislation that privacy advocates seem concerned about. The proposed law would eliminate potentially stronger, state-level protections that currently exist. While privacy rights groups remain cautiously optimistic about the APRA’s potential, they are also wary of its proposed preemption of state laws. If the currently proposed regulations look strong, the legislative process is just beginning and there’s no telling what the federal law may look like after what is sure to be a long, combative policymaking process.

    Here’s a quick look at what the legislation currently promises, and what privacy advocates are saying about it.

    The right to access, control, and delete

    The American Privacy Rights Act would create broad protections for Americans’ data, giving consumers the ability to access, control, and delete data covered by the legislation. The policy would give all Americans the power to request information from entities that have collected data about them. Businesses that fall under the law would need to comply with consumers’ requests within “specified timeframes,” the bill states. The bill allows certain exemptions from these mandates, including small businesses (which are defined as companies making “$40,000,000 or less in annual revenue” or that collect, process, retain, or transfer “the covered data of 200,000 or fewer individuals”), as well as governments, and “entities working on behalf of governments.”

    Data minimization

    The bill would also mandate something called “data minimization.” The idea here is to reduce the overall amount of information that companies can collect about web users. Bill backers say that companies covered by the legislative will not be able to “collect, process, retain, or transfer data beyond what is necessary, proportionate, or limited to provide or maintain a product or service requested by an individual, or provide a communication reasonably anticipated in the context of the relationship, or a permitted purpose.” Again, while that sounds good, the devil is in the details here, and it’s not totally clear yet what this sort of data minimization would look like in real life.

    What is covered data?

    The bill defines the data covered by the legislation as follows:

    …information that identifies or is linked or reasonably linkable to an individual or device. It does not include de-identified data, employee data, publicly available information, inferences made from multiple sources of publicly available information that do not meet the definition of sensitive covered data and are not combined with covered data, and information in a library, archive, or museum collection subject to specific limitations.

    Empowering the FTC

    Enforcement of the law would take place at both the federal and state levels. Most notably, the Federal Trade Commission would be tasked with developing regulations and technical specifications for a “centralized mechanism for individuals to exercise” their opt-out rights, as well as other technical issues surrounding the execution of the legislation, the bill states. At the same time, the bill gives authority to “State attorneys general, chief consumer protection officers, and other officers of a State in Federal district court” to pursue enforcement actions against companies that violate the law.

    Taking aim at the data broker industry

    The bill also targets data brokers. Under the new legislation, the FTC would be mandated to establish a data broker registry that could be used by consumers to identify which companies are brokers and to opt out of data collection by those firms. All data brokers that collect data on more than 5,000 people would be forced to re-register with the federal registry every year. At the same time, brokers would also be forced to maintain their own websites that identify them as data brokers and include a tool for consumers to opt out.

    Private right of action

    A longstanding desire for privacy advocates has been a private right of action—which is a mechanism allowing individual consumers to sue companies that have violated their rights. A number of state privacy laws have failed to include this. Under the current version of the APRA, consumers would be given a private right of action, allowing them to file litigation against companies that have demonstrably violated their digital privacy rights.

    Privacy advocates remain cautiously optimistic

    Given years of inaction on privacy policy by federal regulators, state governments have passed a number of strong privacy laws over the past decade. Some of those laws, like California’s CCPA, have been quite strong. The newly proposed federal law openly acknowledges that it would eliminate “the existing patchwork of state comprehensive data privacy laws” and establish in its place “robust enforcement mechanisms to hold violators accountable.” The fact that the APRA would pre-empt state laws worries some privacy advocates who fear the potential for a watered-down federal law. The fact that the APRA may seem strong now doesn’t mean much, since it could easily be neutered by lobbyists during the legislative process.

    Caitriona Fitzgerald, the deputy director at the Electronic Privacy Information Center, said that the federal law’s preemption of state-level regulation is only appropriate if it ends up being a strong law. “From our perspective—in an ideal world—it would not preempt state laws, it would allow states to pass stronger laws,” said Fitzgerald. “We recognize that compromise is necessary and that this is a big sticking point. If it’s going to preempt state laws, it needs to be stronger than existing state laws and regulations. We’re still evaluating the bill to determine whether that’s the case.”

    Other privacy advocates, like the Surveillance Technology Oversight Project (STOP), expressed similar concerns. “The ADPPA does offer strong privacy protections, especially data minimization rules,” said STOP Communications Director Will Owen. “But the bill falls short by preempting states from taking even stronger action, should they so choose. Worst of all, the ADPPA preempts states from enforcing protections, leaving it solely up to the U.S. executive branch, which has been fickle in enforcing Americans’ privacy rights.”

    Cody Venzke, senior policy counsel at the ACLU, said his organization remained “concerned this bill’s broad preemption of state laws will freeze our ability to respond to evolving challenges posed by technology.”

    [ad_2]

    Lucas Ropek

    Source link

  • Can You Have a Fun Vacation on Ozempic?

    Can You Have a Fun Vacation on Ozempic?

    [ad_1]

    At Christmas dinner, Jenny Burriss remembers eating exactly one bite of beef before feeling full. She had just upped her dose of semaglutide—the diabetes and obesity drug better known by the brand names Ozempic and Wegovy—and her appetite had plummeted. She had also lost her taste for alcohol, a side effect of the drug. So before her vacation a couple of months later, she decided to skip a dose. She was going to Disney World, and she wanted to enjoy the food—at least a little.

    She was indeed hungrier after skipping her weekly injection, but not ravenously so. At the Biergarten buffet in Epcot’s Germany pavilion—where she might have once piled her plate high, justifying to herself that, after all, this is vacation—she was satisfied by just a small taste of everything. At the French pavilion, she savored a Grand Marnier orange slush. She didn’t lose weight at Disney World, but she didn’t gain any either.

    Semaglutide works by suppressing the appetite and promoting a feeling of fullness. More fundamentally though, it works by altering one’s relationship with food. Doctors see the drug as a powerful biochemical tool to help patients build healthy long-term habits. Eating becomes a source not of comfort or pleasure, but simply of sustenance. “It takes a little bit of the enjoyment out of it,” Burriss told me. “But that’s healthy,” she added, for someone like her, who had a compulsive relationship with food. Semaglutide has helped her lose about 40 pounds. As the drug has exploded in popularity for weight loss, though, people who use semaglutide to reset their eating habits are navigating a world where food and the anticipation of it are still central to celebration. Semaglutide is meant to be taken regularly as a lifelong drug. So what to do on vacation, when enjoyment is kind of the point?

    For some, deciding to forgo the dose while traveling is just a practical consideration. Semaglutide’s side effects usually taper off as the body adjusts, but they can range from the mildly inconvenient to the terribly uncomfortable: nausea, vomiting, fatigue, constipation, diarrhea, heartburn, sulfur burps. No one wants to get hit with a bout of diarrhea as a plane is taking off.

    For others, staying on the drug removes the compulsion and distraction of thinking about food. They enjoy that peace, even on vacation. Semaglutide quiets what some patients call the “food noise” in their brains: waking up in the morning and immediately wondering what to eat today. Mexican? Pizza? Oh, let me look at some menus. It can be overwhelming to experience and exhausting to constantly counter. Fatima Cody Stanford, an obesity-medicine doctor at Harvard, told me that her patients on semaglutide like being able to attend a wedding or a party “without having to worry about overindulging.” Janice Jin Hwang, an obesity-medicine doctor at the UNC School of Medicine, says she tells patients not to see vacations as cheat days. “I don’t like to make it a dichotomy where it’s your normal time and your vacation time,” she says, advocating instead for a more balanced approach all the time.

    People who want to skip while on vacation, though, are swapping tips and experiences online, sometimes in lieu of official medical advice. By and large, those I spoke with, like Burriss, told me that they were looking for a middle ground, not to go completely overboard on food. “I certainly didn’t want to pig out,” says Sarah, who skipped a dose for a 10-year-anniversary trip to the Bahamas. “I just didn’t want to have that weird nauseous feeling or not be able to enjoy wine.” Sarah, whose last name I’m not using to protect her medical privacy, has always loved researching the best restaurants on vacation. This time, she felt some of the thrill of anticipation, but she ate moderately and chose healthy options, such as fresh fish. Allyson Gelman, who skipped while on vacation in Mexico City, told me she still ended up canceling an eagerly awaited 12-course tasting menu. When she eats too much or too unhealthily on semaglutide, she has to vomit; she’s sometimes had to run to the bathroom after overdoing it in a nice restaurant. In Mexico City, she could still feel the drug’s effects lingering in her system, and she knew she wasn’t getting through 12 courses without throwing up.

    Semaglutide does take several weeks to clear from the body, so skipping just one dose attenuates but doesn’t eliminate the effects of the drug. Marnie, whom I’m also identifying by only her first name for medical privacy, has been regularly taking her prescribed Wegovy every other week. In the second week, she can feel her side effects start to fade and her hunger start to return. For her, skipping is largely about managing her side effects, because the drug still leaves her very tired. She’s probably losing weight more slowly this way, she says, but she’s okay with that. In certain cases, Stanford, the doctor at Harvard, told me she has instructed patients who don’t need the full dose for weight loss to go longer between injections to modulate severe side effects. (Bafflingly, she’s found that insurance won’t cover a smaller-dose injection pen.)

    The explosion of interest in semaglutide is so new, though, that doctors and patients alike are still figuring out what it means in the long term—not just in two or three years, but in 20 or 30. How long do the effects last, and how permanent are these new habits? Burriss believes that, for her, there is room for the occasional indulgence, during a special event or vacation. “It’s not an everyday thing,” she said. And indulging while on semaglutide is still nothing like bingeing without it.

    [ad_2]

    Sarah Zhang

    Source link